Research Studies & Clinical Trials

Overview/Purpose

Antibodies that develop naturally against HIV recognize and attach to one part of the virus so that the body’s immune system can try to attack it. Antibodies are usually made by a person’s own immune system, but they can also be manufactured as a drug. SAR441236 has been manufactured to attach to three parts of the HIV virus at the same time, and to neutralize (or block) the ability of the virus to infect more cells.

A5377 is the first study of SAR441236 in humans. This study will enroll two groups of people with HIV: Arm A—people who are on an anti-HIV regimen with an undetectable HIV viral load will receive either SAR441236 or placebo in four increasing dosing groups; and Arm B—people who have never received anti-HIV medications will receive SAR441236 in four increasing dosing groups.

Interested in Volunteering?

This UCLA research study is for people living with HIV who are not currently on ART.

You may qualify if you:

• Are 18 years of age or older
• Are HIV+
• Have a CD4+ cell count of at least 350
• Are not currently taking antiretrovirals (ART)
• Are willing to start ART after 28 days on the study
• Have no Hepatitis B or C infection

Principal Investigator:

Raphael Landovitz, MD, MSc

For more information, contact the UCLA CARE Center at:

[email protected]
310-557-9062

If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.

 

Additional Resources:

actgnetwork.org/studies/a5377-tri-specific-antibody

clinicaltrials.gov/ct2/show/NCT03705169